Charles Schwab
RLAY icon

Charles Schwab’s Relay Therapeutics RLAY Stock Holding History

Charles Schwab’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1M Buy
1,500,817
+388,926
+35% +$5.65M ﹤0.01% 1628
2026
Q1 		$11.1M Sell
1,111,891
-24,811
-2% -$222K ﹤0.01% 2047
2025
Q4 		$9.62M Buy
1,136,702
+25,371
+2% +$181K ﹤0.01% 2163
2025
Q3 		$5.8M Buy
1,111,331
+5,071
+0.5% +$19.3K ﹤0.01% 2370
2025
Q2 		$3.83M Buy
1,106,260
+41,402
+4% +$123K ﹤0.01% 2445
2025
Q1 		$2.79M Buy
1,064,858
+54,051
+5% +$212K ﹤0.01% 2511
2024
Q4 		$4.16M Sell
1,010,807
-24,982
-2% -$136K ﹤0.01% 2418
2024
Q3 		$7.33M Buy
1,035,789
+214,398
+26% +$1.6M ﹤0.01% 2182
2024
Q2 		$5.36M Sell
821,391
-90,766
-10% -$620K ﹤0.01% 2334
2024
Q1 		$7.57M Buy
912,157
+34,344
+4% +$335K ﹤0.01% 2124
2023
Q4 		$9.66M Buy
877,813
+163,008
+23% +$1.38M ﹤0.01% 2002
2023
Q3 		$6.01M Buy
714,805
+42,411
+6% +$456K ﹤0.01% 2173
2023
Q2 		$8.45M Buy
672,394
+18,512
+3% +$230K ﹤0.01% 1984
2023
Q1 		$10.8M Sell
653,882
-561
-0.1% -$10.1K ﹤0.01% 1839
2022
Q4 		$9.78M Buy
654,443
+35,476
+6% +$679K ﹤0.01% 1871
2022
Q3 		$13.8M Buy
618,967
+73,483
+13% +$1.61M 0.01% 1640
2022
Q2 		$9.14M Buy
545,484
+894
+0.2% +$19.2K ﹤0.01% 1881
2022
Q1 		$16.3M Buy
544,590
+16,572
+3% +$402K ﹤0.01% 1688
2021
Q4 		$16.2M Buy
528,018
+99,696
+23% +$3.15M ﹤0.01% 1737
2021
Q3 		$13.5M Buy
428,322
+205,352
+92% +$6.91M ﹤0.01% 1837
2021
Q2 		$8.16M Buy
222,970
+28,779
+15% +$948K ﹤0.01% 2106
2021
Q1 		$6.71M Buy
194,191
+34,628
+22% +$1.5M ﹤0.01% 2155
2020
Q4 		$6.63M Buy
159,563
+4,520
+3% +$204K ﹤0.01% 2083
2020
Q3 		$6.6M Buy
+155,043
New +$5.91M ﹤0.01% 1936

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Charles Schwab's RLAY Position: Q2 2026 in Review

Charles Schwab increased its Relay Therapeutics (RLAY) stake by 35% in Q2 2026, buying an estimated $5.65M and bringing the position to 1,500,817 shares worth $28.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Charles Schwab first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Charles Schwab held 1,500,817 shares of Relay Therapeutics worth $28.1M as of Q2 2026.
  • Charles Schwab bought 388,926 Relay Therapeutics shares in Q2 2026, an estimated $5.65M.
  • Relay Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1628 holding.
  • Charles Schwab first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.